CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 139 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 19.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,275,073 | +679.0% | 177,373 | +372.0% | 0.00% | – |
| Q2 2023 | $677,138 | +9.8% | 37,577 | -2.2% | 0.00% | – |
| Q1 2023 | $616,865 | +84.4% | 38,410 | +110.1% | 0.00% | – |
| Q4 2022 | $334,543 | -8.6% | 18,281 | -2.0% | 0.00% | – |
| Q3 2022 | $366,000 | -6.2% | 18,647 | -10.9% | 0.00% | – |
| Q2 2022 | $390,000 | -8.2% | 20,919 | +8.1% | 0.00% | – |
| Q1 2022 | $425,000 | -92.1% | 19,343 | -89.8% | 0.00% | -100.0% |
| Q4 2021 | $5,404,000 | +1457.3% | 190,235 | +1052.9% | 0.00% | – |
| Q3 2021 | $347,000 | +34.5% | 16,501 | +20.4% | 0.00% | – |
| Q2 2021 | $258,000 | – | 13,702 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 3,375,169 | $84,379,000 | 7.91% |
| RA Capital Management | 1,875,209 | $46,880,000 | 2.52% |
| Perceptive Advisors | 2,587,953 | $64,698,000 | 1.48% |
| New Leaf Venture Partners, L.L.C. | 167,700 | $4,193,000 | 1.12% |
| Orbimed Advisors | 2,039,282 | $50,982,000 | 0.79% |
| Eventide Asset Management | 803,839 | $20,096,000 | 0.61% |
| Novo Holdings A/S | 135,009 | $3,375,000 | 0.47% |
| Opaleye Management Inc. | 36,000 | $900,000 | 0.27% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 490,000 | $12,250,000 | 0.03% |
| Baker Brothers Advisors | 132,985 | $3,325,000 | 0.02% |